JP2005075834A5 - - Google Patents

Download PDF

Info

Publication number
JP2005075834A5
JP2005075834A5 JP2004256724A JP2004256724A JP2005075834A5 JP 2005075834 A5 JP2005075834 A5 JP 2005075834A5 JP 2004256724 A JP2004256724 A JP 2004256724A JP 2004256724 A JP2004256724 A JP 2004256724A JP 2005075834 A5 JP2005075834 A5 JP 2005075834A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
phenyl
substituted
furyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004256724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005075834A (ja
Filing date
Publication date
Priority claimed from US10/653,859 external-priority patent/US20040077702A1/en
Application filed filed Critical
Publication of JP2005075834A publication Critical patent/JP2005075834A/ja
Publication of JP2005075834A5 publication Critical patent/JP2005075834A5/ja
Pending legal-status Critical Current

Links

JP2004256724A 2003-09-03 2004-09-03 神経変性疾患の処置 Pending JP2005075834A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/653,859 US20040077702A1 (en) 2001-09-14 2003-09-03 Treatment of nuerodegenerative diseases

Publications (2)

Publication Number Publication Date
JP2005075834A JP2005075834A (ja) 2005-03-24
JP2005075834A5 true JP2005075834A5 (https=) 2007-10-18

Family

ID=34136658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004256724A Pending JP2005075834A (ja) 2003-09-03 2004-09-03 神経変性疾患の処置

Country Status (8)

Country Link
US (1) US20040077702A1 (https=)
EP (1) EP1512400B1 (https=)
JP (1) JP2005075834A (https=)
KR (1) KR20050024272A (https=)
CN (1) CN1626077A (https=)
AT (1) ATE460161T1 (https=)
DE (1) DE602004025885D1 (https=)
TW (1) TW200510329A (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
US20080200557A1 (en) * 2004-07-07 2008-08-21 Caritas St. Elizabeth Hospital Of Boston, Inc. Method for Inhibiting Lipid Peroxidation
US20080252028A1 (en) * 2007-04-16 2008-10-16 Ming-Tai Huang Shock absorbing device for toy stroller
WO2008136772A1 (en) * 2007-05-02 2008-11-13 Agency For Science, Technology And Research Method of monitoring retinopathy
US20140163082A1 (en) 2011-05-06 2014-06-12 King Khalid Eye Specialist Hospital Pyrazolyl compounds for use in reversing reactive gliosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105149A (en) * 1870-07-05 Egbert l
US4355A (en) * 1846-01-15 Beehive
JP2928079B2 (ja) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途
US7115661B1 (en) * 1999-12-29 2006-10-03 Queen's University At Kingston Methods and compositions for mitigating pain
US5760230A (en) * 1996-10-11 1998-06-02 Bayer Aktiengesellschaft 4, 4'-bridged bis-2, 4-diaminoquinazolines
DE19642255A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
GB9920566D0 (en) * 1999-08-31 1999-11-03 Univ London Screen for axon viability
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
GB0002666D0 (en) * 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
DE60201921T2 (de) * 2001-01-24 2005-10-06 Yung Shin Pharmaceutical Ind. Co., Ltd. Kondensierte Pyrazolverbindungen
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h-吲唑化合物
US7049334B2 (en) * 2001-09-14 2006-05-23 Carlsbad Technology, Inc. Enhancement of learning and memory and treatment of amnesia
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
US20050089473A1 (en) * 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier

Similar Documents

Publication Publication Date Title
JP2005521713A5 (https=)
CN113784970A (zh) Erk抑制剂及其应用
JP2006507313A5 (https=)
JP2010511721A5 (https=)
JP2005523922A5 (https=)
JP2009536221A5 (https=)
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
JP2018533593A5 (https=)
JP2013537203A5 (https=)
CA2505489A1 (en) Pyrrolobenzodiazepines
CY1110986T1 (el) Αζολια ως αναστολεις της αποκαρβοξυλασης μηλονυλο-συνενζυμου α χρησιμα ως μεταβολικοι διαμορφωτες
JP2007522220A5 (https=)
JP2012508252A5 (https=)
JP2004500426A5 (https=)
JP2005511547A5 (https=)
JP2007504235A5 (https=)
JP2002527414A5 (https=)
JP2010535706A5 (https=)
JP2006504738A5 (https=)
JP2010534246A5 (https=)
JP2013513607A5 (https=)
JP2007517037A5 (https=)
JP2010514734A5 (https=)
JP2012511558A5 (https=)
JP2005075834A5 (https=)